Topic : TKIs

Other Topics :

TKI use around the world

TKIs have been the standard of care for CML for over a decade, and a number of studies have collected data on their use. There are some interesting differences from one country to another.
Continue Reading →

Updated trial results for Bosulif

One of the more recent TKIs (tyrosine kinase inhibitors) used to treat CML is Bosulif (bosutinib), which has been approved in many countries for people who have resistance or intolerance to another TKI.
Continue Reading →

What is a “response”?

When you are first diagnosed with chronic myelogenous leukemia, the first goal is to reduce the very high number of white blood cells (WBC) in the blood stream.
Continue Reading →

Why should you take your meds?

A great deal of attention has focused on the possibility that people with a deep response to their CML medication may be able to stop treatment at some point. But perhaps a more important question is: why keep taking a medication every day? Is this necessary, or can I take a break?
Continue Reading →

ASH 2014: Newer treatments for CML – Part 4

Gleevec has long been the gold standard of CML treatment. But more potent second-generation medications (Tasigna and Sprycel) can now be used as first-choice treatments instead of Gleevec. So how well do these two drugs perform in controlling CML?
Continue Reading →

ASH 2014: Newer treatments for CML – Part 3

Part 3 of our ASH 2014 coverage looks at novel therapies and new treatment approaches for CML.
Continue Reading →

ASH 2014: An update on stopping treatment – Part 2

Stopping treatment is perhaps the hottest topic in CML research, and a number of new studies presented at ASH 2014 looked at this issue.
Continue Reading →

ASH 2014: Survival in the TKI age – Part 1

People with CML who respond to a TKI (tyrosine kinase inhibitor) can expect to live a little bit longer than similarly aged people without CML in the general population, according to a new analysis by researchers at the MD Anderson Cancer Center, Houston, Texas.
Continue Reading →

New 2015 guidelines for CML

The U.S. National Comprehensive Cancer Network (NCCN) has published new guidelines for the treatment of chronic myelogenous leukemia (O’Brien and colleagues).
Continue Reading →

Good treatment response in older people with CML

In clinical trials of new medications for chronic myelogenous leukemia, the people enrolled in the study are aged 18 and older, with “older” usually defined as 65 or 70 years.
Continue Reading →